|Ms. Nancy S. Lurker||Pres, CEO & Director||736.41k||N/A||1957|
|Mr. George O. Elston||CFO & Head of Corp. Devel.||489.15k||N/A||1965|
|Dr. Dario A. Paggiarino||Sr. VP & Chief Medical Officer||541.39k||N/A||1957|
|Mr. Said Saim||Chief Technology Officer||N/A||N/A||1958|
|Mr. Ron I. Honig Esq.||Sr. VP, Gen. Counsel & Company Sec.||N/A||N/A||N/A|
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
EyePoint Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 6. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 3; Compensation: 10.